CBCassandra Brookes

Cassandra Brookes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cassandra Brookes has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multicomponent structured health behaviour intervention to improve physical activity in long-distance HGV drivers: the SHIFT cluster RCT

    by Stacy A Clemes, Veronica Varela-Mato, Danielle H Bodicoat, Cassandra L Brookes, Yu-Ling Chen, Edward Cox, Charlotte L Edwardson, Laura J Gray, Amber Guest, Vicki Johnson, et al.

    Background: Long-distance heavy goods vehicle drivers are exposed to a multitude of risk factors associated with their occupation. The working environment of heavy goods vehicle drivers provides limited opportunities for a healthy lifestyle, and, consequently, heavy goods vehicle drivers exhibit higher than nationally representative rates of obesity and obesity-related comorbidities, and are underserved in terms of health promotion initiatives.Objective: The aim of this trial was to test the effectiveness and cost-effectiveness of the multicomponent Structured Health Intervention For Truckers (SHIFT) programme, compared with usual care, at both 6 months and 16–18 months.Design: A two-arm cluster randomised controlled trial, including a cost-effectiveness analysis and process evaluation.Setting: Transport depots throughout the Midlands region of the UK.Participants: Heavy goods vehicle drivers.Intervention: The 6-month SHIFT programme included a group-based interactive 6-hour education session, health coach support and equipment provision [including a Fitbit®(Fitbit Inc., San Francisco, CA, US) and resistance bands/balls to facilitate a ‘cab workout’]. Clusters were randomised following baseline measurements to either the SHIFT arm or the control arm.Main outcome measures: Outcome measures were assessed at baseline, with follow-up assessments occurring at both 6 months and 16–18 months. The primary outcome was device-measured physical activity, expressed as mean steps per day, at 6-month follow-up. Secondary outcomes included device-measured sitting, standing, stepping, physical activity and sleep time (on any day, workdays and non-workdays), along with adiposity, biochemical measures, diet, blood pressure, psychophysiological reactivity, cognitive function, functional fitness, mental well-being, musculoskeletal symptoms and work-related psychosocial variables. Cost-effectiveness and process evaluation data were collected.Results: A total of 382 participants (mean ± standard deviation age: 48.4 ± 9.4 years; mean ± standard deviation body mass index: 30.4 kg/m2 ± 5.1 kg/m2; 99% male) were recruited across 25 clusters. Participants were randomised (at the cluster level) to either the SHIFT arm (12 clusters,n = 183) or the control arm (13 clusters,n = 199). At 6 months, 209 (54.7%) participants provided primary outcome data. Significant differences in mean daily steps were found between arms, with participants in the SHIFT arm accumulating 1008 more steps per day than participants in the control arm (95% confidence interval 145 to 1871 steps;p = 0.022), which was largely driven by the maintenance of physical activity levels in the SHIFT arm and a decline in physical activity levels in the control arm. Favourable differences at 6 months were also seen in the SHIFT arm, relative to the control arm, in time spent sitting, standing and stepping, and time in moderate or vigorous activity. No differences between arms were observed at 16–18 months’ follow-up. No differences were observed between arms in the other secondary outcomes at either follow-up (i.e. 6 months and 16–18 months). The process evaluation demonstrated that the intervention was well received by participants and that the intervention reportedly had a positive impact on their health behaviours. The average total cost of delivering the SHIFT programme was £369.57 per driver, and resulting quality-adjusted life-years were similar across trial arms (SHIFT arm: 1.22, 95% confidence interval 1.19 to 1.25; control arm: 1.25, 95% confidence interval 1.22 to 1.27).Limitations: A higher (31.4%) than anticipated loss to follow-up was experienced at 6 months, with fewer (54.7%) participants providing valid primary outcome data at 6 months. The COVID-19 pandemic presents a major confounding factor, which limits our ability to draw firm conclusions regarding the sustainability of the SHIFT programme.Conclusion: The SHIFT programme had a degree of success in positively impacting physical activity levels and reducing sitting time in heavy goods vehicle drivers at 6-months; however, these differences were not maintained at 16–18 months.Future work: Further work involving stakeholder engagement is needed to refine the content of the programme, based on current findings, followed by the translation of the SHIFT programme into a scalable driver training resource.Trial registration: This trial is registered as ISRCTN10483894.Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme and will be published in full inPublic Health Research; Vol. 10, No. 12. See the NIHR Journals Library website for further project information.


  • Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial

    by Ahmed Javid Yousuf, Seid Mohammed, Liesl Carr, Mohammadali Yavari Ramsheh, Koirobi Haldar, Adam K A Wright, Petr Novotny, Sarah Parker, Sarah Glover, Joanne Finch, et al.

    Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory airways disease. The epithelial-derived ‘alarmin’ IL-33 and its receptor ST2 have been implicated in airway inflammation and infection. We sought to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. Methods: We undertook a single-centre, randomised, double-blinded, placebo-controlled, phase IIa trial in moderate-to-very severe COPD. Participants received astegolimab 490mg (n=42) or placebo (n=39), every 4 weeks over 44 weeks. Primary endpoint was exacerbation rate over 48 weeks with pre-specified subgroup analysis by baseline blood eosinophil count. Secondary endpoints included Saint George’s Respiratory Questionnaire for COPD (SGRQ-C), FEV1, blood and sputum cell counts, and safety and tolerability. Results: The 48-week exacerbation rate in the astegolimab group relative to placebo was 0.78 (0.53 -0 1.14; p=0.195) in the whole group and 0.69 (0.39 - 1.21) and 0.83 (0.49 - 1.40) in subjects below or above the median baseline blood eosinophil count (170 cells/µL). In the astegolimab group versus placebo the mean difference for SGRQ-C and FEV1 was –3.3 (-6.4 to -0.2; p=0.039) and 40ml (-10 to 90; p=0.094), respectively. The differences in geometric mean ratios for blood and sputum eosinophil counts were 0.59 (0.51 - 0.69; p<0.001) and 0.25 (0.19 - 0.33; p<0.001). Incidence of treatment-emergent adverse events was similar between groups. Conclusion: Astegolimab did not reduce 48-week COPD exacerbation rate significantly in the whole group, subgroup analyses suggested more benefit in subjects with lower blood eosinophil counts.

  • Abstract P4-11-05: Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study

    by John Ms Bartlett, Cassandra L Brookes, Fu J Yan, Mary Anne Quintayo, Jane Bayani, Jane Starczynski, Cornelis Jh van de Velde, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, et al.

    Introduction: Several studies have suggested that AR expression, particularly in luminal cancers following endocrine therapy, may be associated with improved outcome in early breast cancer. We performed an analysis of AR expression in the TEAM pathology cohort to test the hypothesis that AR would represent an independent predictor of residual risk following adjuvant endocrine therapy. Methods: Triplicate 0.6mm2 TMA cores from the TEAM pathology cohort (N=4,598) were stained using AR clone ER179(2) on a Ventana automated staining platform and analysed by image analysis using the Ariol Image analysis platform. Continuous histoscores were generated as previously described (Bartlett et al, JCO 2011). Results: AR histoscores were generated from 3866/4598 (84%) of available cases. Median AR histoscores were 227 (interquartile range 195-262). In a univariate Cox proportional hazard model with AR histoscore as a continuous variable, increased AR histoscores were significantly associated with a reduced hazard of distant disease relapse or death from breast cancer. The hazard ratio (HR) associated with a 50 unit increase in the histoscore was 0.88, 95% confidence interval (95%CI) 0.83-0.93, PPP=0.006. However, a multivariate model of AR histoscore including other known prognostic factors such as age, grade, tumour size, number of positive nodes, HER2 status, ER and PgR histoscores found AR histoscore was not independently prognostic for distant relapse or death (HR=1.00, 95% CI 0.94-1.06, P=0.96). There was no significant interaction between AR expression and type of endocrine treatment (Tamoxifen →exemestane versus exemestane alone) in either univariate (HR 1.003 95%CI 0.91-1.11, p=0.96) or multivariate (HR 0.92, 95%CI 0.81-1.04, p=0.18) analysis. Logistic regression analysis was performed to investigate the association between AR histoscore (2 groups above and below the median) and the known prognostic factors mentioned above. Increased AR histoscore is associated with good risk factors; young age, low grade, small tumours, decreasing ki67 and increasing ER and PgR histoscores. Conclusion: AR expression is common in luminal breast cancers. However, in this study AR histoscore does not add residual risk information beyond what can already be assessed using conventional prognostic factors. High AR expression is associated with good prognostic factors, including young age, low tumour grade, small tumour size, lower Ki67 and higher ER/PgR expression. Citation Format: John MS Bartlett, Cassandra L Brookes, Fu J Yan, Mary Anne Quintayo, Jane Bayani, Jane Starczynski, Cornelis JH van de Velde, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel W Rea. Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-11-05.

  • Abstract P2-05-12: Signatures of endocrine resistance in the tamoxifen and exemestane adjuvant multinational trial (TEAM)-UK cohort

    by Jane Bayani, Mary Anne Quintayo, Cindy Q Yao, Syed Haider, Cassandra Brookes, Paul C Boutros, John Ms Bartlett, Daniel W Rea

  • Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant

    by E. Nikolousis, S. Robinson, S. Nagra, C. Brookes, F. Kinsella, S. Tauro, S. Jeffries, M. Griffiths, P. Mahendra, M. Cook, et al.